Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
August 28 2024 - 8:00AM
Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS),
a clinical-stage biopharmaceutical company focused on developing
and commercializing novel therapeutics to treat a wide range of
patients with disorders that are linked to dysfunctional signaling
of the transforming growth factor-beta (“TGF-ß”) family of
proteins, today announced that Keros’ Chair and Chief Executive
Officer Jasbir S. Seehra, Ph.D., will present at the following
healthcare conferences:
Morgan Stanley
22nd Annual Global Healthcare
Conference
- Date and Time:
Wednesday, September 4, 2024 at 4:05 p.m. Eastern time
- Link:
https://cc.webcasts.com/morg007/090424a_js/?entity=151_MYXXV3G
- Format: Fireside
Chat Presentation
2024 Wells Fargo Healthcare Conference
- Date and Time:
Thursday, September 5, 2024 at 10:15 a.m. Eastern time
- Link:
https://cc.webcasts.com/well001/090424a_js/?entity=90_NG8VPD0
- Format: Fireside
Chat Presentation
2024 Cantor Global Healthcare Conference
- Date and Time:
Thursday, September 19, 2024 at 8:35 a.m. Eastern Time
- Link:
https://wsw.com/webcast/cantor22/kros/2112021
- Format: Fireside
Chat Presentation
For each presentation, an archived replay will be accessible in
the Investors section of the Keros website at
https://ir.kerostx.com for up to 90 days following the conclusion
of each event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on
developing and commercializing novel therapeutics to treat a wide
range of patients with disorders that are linked to dysfunctional
signaling of the TGF-ß family of proteins. The Company is a leader
in understanding the role of the TGF-ß family of proteins, which
are master regulators of the growth, repair and maintenance of a
number of tissues, including blood, bone, skeletal muscle, adipose
and heart tissue. By leveraging this understanding, Keros has
discovered and is developing protein therapeutics that have the
potential to provide meaningful and potentially disease-modifying
benefit to patients. Keros’ lead product candidate, elritercept
(KER-050), is being developed for the treatment of low blood cell
counts, or cytopenias, including anemia and thrombocytopenia, in
patients with myelodysplastic syndromes and in patients with
myelofibrosis. Keros’ second product candidate, cibotercept
(KER-012), is being developed for the treatment of pulmonary
arterial hypertension for the treatment of cardiovascular
disorders. Keros’ third product candidate, KER-065, is being
developed for the treatment of obesity and for the treatment of
neuromuscular diseases.
Investor Contact:Justin
Frantzjfrantz@kerostx.com617-221-6042
Keros Therapeutics (NASDAQ:KROS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Keros Therapeutics (NASDAQ:KROS)
Historical Stock Chart
From Oct 2023 to Oct 2024